Literature DB >> 19717382

Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.

James R Berenson1, Ori Yellin.   

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell disorder characterized by the presence of a serum monoclonal immunoglobulin (M-protein) at <or= 3 g/dL. It is an asymptomatic premalignant disorder that can progress to multiple myeloma and related B-cell disorders. Recent studies have suggested the association of MGUS with enhanced bone loss and debilitating skeletal complications, particularly vertebral compression fractures (VCFs) often leading to back pain. Early identification of MGUS and evaluation of bone status will facilitate prophylactic treatment with bisphosphonates to increase bone density and likely reduce the risk of fractures as well as identify patients with VCFs who might benefit from early surgical intervention. With proper diagnostic and treatment strategies, these patients will experience improved outcomes and quality of life.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19717382     DOI: 10.3816/CLM.2009.n.061

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma        ISSN: 1557-9190


  3 in total

Review 1.  Development of early treatment strategies for high-risk myeloma precursor disease in the future.

Authors:  Ola Landgren; S Vincent Rajkumar
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

Review 2.  Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.

Authors:  Adam J Waxman; Michael Kuehl; Arun Balakumaran; Brendan Weiss; Ola Landgren
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2010-08

3.  Data quality of the monoclonal gammopathy of undetermined significance diagnosis in a hospital registry.

Authors:  Henrik Gregersen; Caroline Brenner Larsen; Anne Haglund; Rikke Mortensen; Niels Frost Andersen; Mette Nørgaard
Journal:  Clin Epidemiol       Date:  2013-08-27       Impact factor: 4.790

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.